August 16

Lift Veil on Research Funding

Indeed, leading researchers from powerful and prestigious academic institutions routinely fail to disclose conflicts of interest to readers of JAMA and other leading medical journals.  Disclosure of authors’ financial ties—as everyone involved must surely realize—might impede the commercial value of these reports:
“At issue,” the Globe notes, “is the danger that researchers who receive money from for-profit companies — whether for speaking fees, consulting, or conducting drug trials — may, consciously or unconsciously, be biased by that money.”

The shocking disclosure by Forbes and The Wall Street Journal, that The New England Journal of Medicine (NEJM) failed to disclose to physicians and the public that the authors of an influential report in its publication omitted to report three Vioxx deaths, there was much hand wringing by journal editors deploring industry’s influence on journals—but no action. In an editorial, Can We Tame the Monster? BMJ editor, Dr. Fiona Godlee, recommended cutting the umbilical cord connecting researchers and the drug industry.  However, she fled under cover when a letter to the editor was submitted to the BMJ in which a series of recent case examples reported in several major news outlets during the month of July were reviewed and journal editors were called to task for failure use their authority.

JAMA and Neuropsychopharmacology—the official journal of the American College of Neuropsychopharmacology—shared the spotlight in the press–both caught off guard. In the case of the editor of Neuropsychopharmacology—his name was penned as lead author of the offending article. The editor of JAMA prefers to acknowledge being snookered repeatedly rather than take action to enforce her journal’s conflict of interest policies. She ignores entirely her public responsibility for the potential harm done by publishing an influential, widely advertised article by 13 researchers from Harvard, UCLA and Emory who urged doctors to continue prescribing antidepressants to pregnant women without at least disclosing their financial ties to antidepressant manufactures.

The editor prefers to put her head in the sand ignoring the fact that doctors—relying on the JAMA article—would advise their pregnant patients to continue on antidepressants. The women would unwittingly be exposing their unborn infants to risk of persistent pulmonary hypertension and brain damage by following doctors’ prescribed treatment.

The Globe reports that when Dr Catherine DeAngelis was asked whether JAMA would accept articles by these psychiatrists, the editor said she “wouldn’t blink twice" if Cohen and his colleagues submitted another article to JAMA, adding: “They are very good researchers; they’re good people."

This “forgive and forget” attitude by JAMA editor toward physicians who use JAMA’s pages to promote harm producing treatments demonstrates how participating stakeholders trivialize the corrupting commercial influence on science. It also demonstrates complicity by participating stakeholders—particularly those at the pinnacle of academia—who give each other a pass whenever one of their club is caught publicly in the act of tainting science or promoting worthless or lethal drugs.

JAMA editor’s response: “Joe, do something with your kids!"

Medicine has lost its moral compass: commercial medicine and the culture of greed are destroying the foundation of academic medicine.

For references and links to articles,
See: Sharav V. Journals Must Exercise Their Authority as Gatekeeper, August 1:
See also: Kassirer J. A Cure for Public Distrust, OpEd The Boston Globe.

Contact: Vera Hassner Sharav

Boston Globe
Some seek to lift veil on research funding
Full disclosure urged on money sources
By Carey Goldberg 
August 8, 2006

Three weeks ago, the editor of the prestigious Journal of the American Medical Association called Dr. Joseph B. Martin, dean of Harvard Medical School, and said, as she describes it, “Joe, do something with your kids!"

Dr. Catherine D. DeAngelis, the editor, told the dean that in violation of the journal’s policies, Harvard authors of three recent articles had failed to disclose relevant financial ties with drug companies.

Responding to DeAngelis’ s concerns, Martin told her that he plans to send a letter laying out the conflict-of-interest disclosure requirements for JAMA and another top medical journal to all 8,000 members of the medical school’s faculty, which encompasses most doctors practicing at more than a dozen Boston hospitals and research centers.

The Harvard cases and others like them are fueling mounting concern about potential conflicts of interest in medical research.

At issue is the danger that researchers who receive money from for-profit companies — whether for speaking fees, consulting, or conducting drug trials — may, consciously or unconsciously, be biased by that money.

While some critics say that scientists should accept no money from for-profit companies, DeAngelis and others contend that, at the very least, researchers must reveal any funding they have received that might conceivably influence their findings or recommendations, so that colleagues and patients can judge the authors’ credibility.
JAMA requires authors to sign a statement listing all financial interests that might be perceived as influencing their article and has published these disclosures since 1990.

DeAngelis has undertaken a campaign to enforce her journal’s disclosure requirements and, as part of that effort, posted an editorial online yesterday in which she said she has begun to publicize authors’ failures to follow JAMA’s policies.

In the editorial, DeAngelis singled out Harvard Medical School, saying that it was “somewhat surprising" that three consecutive cases of nondisclosure brought to the journal’s attention by authors or readers involved Harvard authors.
DeAngelis said in a phone interview yesterday that she believes that the Harvard authors’ omissions stemmed from ignorance of the journal’s policies, rather than malice. She said Harvard simply has so many faculty members and hospitals that it is hard to get a message across to everyone.

Martin declined through a spokesman to comment, but confirmed that he planned to send out the 8,000 letters describing the disclosure policies of JAMA and the New England Journal of Medicine. He also planned to discuss with faculty whether Harvard Medical School needs to improve its rules on financial ties.
The conflict-of-interest issue comes up periodically, spokesman Don Gibbons said, and a large committee finished reexamining it a couple of years ago. In the three-page editorial yesterday, DeAngelis points out that it is impossible for medical journals to check the financial ties of each of the thousands of authors whose papers are published every year, and there is no central, up-to-date database on the topic.

JAMA has clarified its rules on disclosure and, when omissions are pointed out, corrects them in print, she wrote. But different journals have different rules, so some confusion is likely, she said. One of the JAMA papers that DeAngelis cited described a major five-year study that found that when women went off antidepressants during pregnancy, their depression was highly likely to recur.  The study, published in February, was funded by the federal government and included no drug company funding.

But a Tufts obstetrician, Dr. Adam C. Urato, wrote to JAMA to complain that its authors had received money from antidepressant manufacturers in the past. His letter, published last month, stated that because the study dealt in part with the question of stopping antidepressants during pregnancy, readers should be aware of the potential for prodrug bias.

The lead author, Dr. Lee S. Cohen of Massachusetts General Hospital, responded in the journal that the study did not address the question of whether “antidepressants as a whole or a particular antidepressant" should be prescribed. He and his colleagues saw no potential conflict of interest.
But in retrospect, he wrote, they should have opted for “utmost transparency," and they support the idea of full disclosure. He reported having received grant money, consulting fees, or speaking fees from a half-dozen drug makers, including Eli Lilly and Co. and GlaxoSmithKline.

DeAngelis said she “wouldn’t blink twice" if Cohen and his colleagues submitted another article to JAMA: “They are very good researchers; they’re good people," she said. A second paper, published in May, found that heart-disease research funded by for-profit companies was more likely to favor new treatments over the old standard of care than research funded by other sources.
The lead author, Dr. Paul Ridker of Brigham and Women’s Hospital, later apologized, saying that while he had received no funding for the study, he had neglected to mention past consulting fees and grant money from a half-dozen drug companies.

The third Harvard-connected paper involved an apparent link between women with a particular kind of migraine and the risk of heart attack and stroke. The study, led by Dr. Tobias Kurth of Brigham and Women’s Hospital and published July 19, found that migraines with aura, visual disturbances like flashing and blind spots, seemed more closely linked to stroke and heart attack than typical migraines.
The study was funded by federal money and a foundation and did not look at treatment options, so the Kurth team reported no potential conflicts. But

DeAngelis wrote in JAMA that all past and present ties with the makers of drugs used to treat migraine or heart disease needed to be disclosed.
In a letter posted on the JAMA website, Kurth reported receiving research grants from three companies that make pain medication. The lesson, Kurth said in a phone interview yesterday, is: “It is best to report any relation to the [journal] editors and let the editors decide whether it’s relevant or not."
Liz Kowalczyk of the Globe staff contributed to this report. Carey Goldberg can be reached at

© Copyright 2006 The New York Times Company
FAIR USE NOTICE: This may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a ‘fair use’ of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.

Subscribe To Our Newsletter!

Sign up and be the first to find out the latest news and articles about what's going on in the medical field.

You may also like

November 21, 2023

Vera Sharav is joining Christine Anderson as special guest for the Make It Your Business event in

Read More
Vera Sharav Joins Christine Anderson for Make It Your Business – Dec 4, 2023 in New Jersey

November 21, 2023

Vera Sharav is premiering the movie Never Again is Now Global in New York City, December 1.

Read More
Never Again is Now Global – Premiere Screening – Dec 1, 2023 in New York City